Open Access Highly Accessed Pre-publication history

Rationale and design of DECISION: a double-blind, randomized, placebo-controlled phase III trial evaluating the efficacy and safety of sorafenib in patients with locally advanced or metastatic radioactive iodine (RAI)-refractory, differentiated thyroid cancer

Marcia S Brose*, Christopher M Nutting, Steven I Sherman, Young Kee Shong, Johannes WA Smit, Gerhard Reike, John Chung, Joachim Kalmus, Christian Kappeler and Martin Schlumberger*

BMC Cancer 2011, 11:349  doi:10.1186/1471-2407-11-349

Pre-publication versions of this article and reviewers' reports

Original Submission - Version 1 Manuscript 23 Mar 2011
Resubmission - Version 2 Manuscript Author's comment 29 Mar 2011
Reviewer's Report Dirk Vordermark 24 Jul 2011
Editorial acceptance 29 Jul 2011
Published 11 Aug 2011